Read by QxMD icon Read

SEER AND lung cancer

Deborah L Goldwasser
The National Lung Screening Trial (NLST) demonstrated that non-small cell lung cancer (NSCLC) mortality can be reduced by a program of annual CT screening in high-risk individuals. However, CT screening regimens and adherence vary, potentially impacting the lung cancer mortality benefit. We defined the NSCLC cure threshold as the maximum tumor size at which a given NSCLC would be curable due to early detection. We obtained data from 518,234 NSCLCs documented in the U.S. SEER cancer registry between 1988 and 2012 and 1,769 NSCLCs detected in the NLST...
December 7, 2016: International Journal of Cancer. Journal International du Cancer
Jeannette Y Lee, Ishwori Dhakal, Corey Casper, Ariela Noy, Joel M Palefsky, Missak Haigentz, Susan E Krown, Richard F Ambinder, Ronald T Mitsuyasu
The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database...
2016: Journal of Cancer Epidemiology
Abhishek Bhandari, Melissa Woodhouse, Samir Gupta
Colorectal cancer (CRC) incidence and mortality are rising among young adults. Our aim was to contrast the relative incidence and mortality of CRC to other common cancers among young adults in the USA. We used Surveillance, Epidemiology, and End Results registry data to compare cancer site-specific and age-specific mortality and incident rates for adults younger than age 50. We summarized extracted data, both overall, and stratified by sex. We found CRC was the third leading cause of cancer death among adults younger than age 50, after breast and lung cancer (1...
November 18, 2016: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
N G Zaorsky, T M Churilla, B L Egleston, S G Fisher, J A Ridge, E M Horwitz, Je Meyer Md
BACKGROUND: The purpose of our study was to characterize the causes of death among cancer patients as a function of objectives: (I) calendar year, (II) patient age, and (III) time after diagnosis. PATIENTS AND METHODS: US death certificate data in SEER Stat 8.2.1 were used to categorize cancer patient death as being due to index-cancer, non-index-cancer, and non-cancer cause from 1973 to 2012. In addition, data were characterized with standardized mortality ratios (SMRs), which provide the relative risk of death compared to all persons...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Alex Herskovic, Bhargava Chitti, Paul Christos, A Gabriella Wernicke, Bhupesh Parashar
OBJECTIVES: Limited work, either retrospective or prospective, has been done to investigate whether or not there is a cause-specific mortality (CSM) or all-cause mortality (ACM) benefit to adding surgery following neoadjuvant treatment for Stage IIIB NSCLC. METHODS: We extracted patients with Stage IIIB NSCLC from the Survival, Epidemiology, and End Results Program (SEER) database treated from 2004 to 2012 with either radiation alone or radiation followed by surgery...
October 14, 2016: World Journal of Surgery
Herbert H Pang, Xiaofei Wang, Thomas E Stinchcombe, Melisa L Wong, Perry Cheng, Apar Kishor Ganti, Daniel J Sargent, Ying Zhang, Chen Hu, Sumithra J Mandrekar, Mary W Redman, Judith B Manola, Richard L Schilsky, Harvey J Cohen, Jeffrey D Bradley, Alex A Adjei, David Gandara, Suresh S Ramalingam, Everett E Vokes
PURPOSE: Under-representation of elderly, women, and racial/ethnic minority patients with cancer in clinical trials is of national concern. The goal of this study was to characterize enrollment trends and disparities by age, sex, and race/ethnicity in lung cancer trials. METHODS: We analyzed data for 23,006 National Cancer Institute cooperative group lung cancer trial participants and 578,476 patients with lung cancer from the SEER registry from 1990 to 2012. The enrollment disparity difference (EDD) and enrollment disparity ratio (EDR) were calculated on the basis of the proportion of each subgroup in the trial population and the US lung cancer population...
September 19, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Christine W Duarte, Adam W Black, F Lee Lucas, Calvin P H Vary
PURPOSE: Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by deficiency in endoglin, an angiogenic protein. We previously showed that HHT, in which systemic endoglin expression is reduced, was associated with better survival outcomes in cancer patients (Duarte et al. in Cancer Epidemiol Biomarkers Prev 23:117-125, 2014). Here, we evaluated whether HHT was associated with reduced cancer incidence. METHODS: A matched case-control analysis using SEER Medicare was conducted to evaluate the effect of HHT on diagnosis with breast, colorectal, lung, or prostate cancer between 2000 and 2007 (n = 633,162)...
September 16, 2016: Journal of Cancer Research and Clinical Oncology
Zoe Wainer, Gavin M Wright, Karla Gough, Marissa G Daniels, Peter Choong, Matthew Conron, Prudence A Russell, Naveed Z Alam, David Ball, Benjamin Solomon
BACKGROUND: Lung cancer has markedly poorer survival in men. Recognized important prognostic factors are divided into host, tumour and environmental factors. Traditional staging systems that use only tumour factors to predict prognosis are of limited accuracy. By examining sex-based patterns of disease-specific survival in non-small cell lung cancer patients, we determined the effect of sex on the prognostic value of additional host factors. METHODS: Two cohorts of patients treated surgically with curative intent between 2000 and 2009 were utilized...
September 14, 2016: ANZ Journal of Surgery
Hari Nathan, Huiying Yin, Sandra L Wong
BACKGROUND: Recent attention has focused on the ability to rescue patients from postoperative complications and prevent short-term mortality. However, it is unknown whether patients rescued from complications after complex cancer resections have long-term survival outcomes similar to those of patients without complications. METHODS: From 2005 to 2009 Surveillance, Epidemiology, and End Results (SEER)-Medicare data, the study identified elderly patients who underwent resection for cancers of the esophagus, lung, or pancreas...
September 12, 2016: Annals of Surgical Oncology
Karyn B Stitzenberg, YunKyung Chang, Angela B Smith, Michael O Meyers, Matthew E Nielsen
BACKGROUND: The burden of readmissions after major cancer surgery is high. Prior work suggests that one-third of readmitted patients are readmitted to a different hospital than where the surgery was performed. The impact of this location of readmission needs to be more thoroughly understood. METHODS: This retrospective cohort study was performed on Surveillance, Epidemiology, and End Results (SEER)-Medicare patients with bladder, esophagus, lung, or pancreas cancer diagnosed from 2001 to 2007 who underwent extirpative surgery and were readmitted within 90 days...
September 9, 2016: Annals of Surgical Oncology
David H Howard, Michael E Chernew, Tamer Abdelgawad, Gregory L Smith, Josephine Sollano, David C Grabowski
Spending on anticancer drugs has risen rapidly over the past two decades. A key policy question is whether new anticancer drugs offer value, given their high cost. Using data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we assessed the value of new cancer treatments in routine clinical practice for patients with metastatic breast, lung, or kidney cancer or chronic myeloid leukemia in the periods 1996-2000 and 2007-11. We found that there were large increases in medical costs, but also large gains in life expectancy...
September 1, 2016: Health Affairs
Daniel M Gilden, Joanna M Kubisiak, Gerhardt M Pohl, Daniel E Ball, David E Gilden, William J John, Stewart Wetmore, Katherine B Winfree
AIM: To assess the cost-effectiveness of first-line pemetrexed/platinum and other commonly administered regimens in a representative U.S. elderly population with advanced nonsquamous non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: This study utilized the Surveillance Epidemiology and End Results (SEER) cancer registry linked to Medicare claims records. The study population included all SEER-Medicare patients diagnosed in 2008-2009 with advanced nonsquamous NSCLC (stages IIIB-IV) as their only primary cancer and who started chemotherapy within 90 days of diagnosis...
August 30, 2016: Journal of Medical Economics
Christopher T Erb, Kevin W Su, Pamela R Soulos, Lynn T Tanoue, Cary P Gross
OBJECTIVES: Recurrence after treatment for non-small cell lung cancer (NSCLC) is common, and routine imaging surveillance is recommended by evidence-based guidelines. Little is known about surveillance patterns after curative intent therapy for early stage NSCLC. We sought to understand recent practice patterns for surveillance of stage I NSCLC in the first two years after curative intent therapy in the Medicare population. MATERIALS AND METHODS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database we selected patients diagnosed with stage I NSCLC between 1998 and 2008...
September 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Emanuela Taioli, Raja Flores
INTRODUCTION: Black lung cancer patients receive surgery less often and have worse survival than white patients. Over the past several decades limited resection has become an acceptable alternative to lobectomy in selected cases, and mediastinal lymph-nodes staging is recommended. The SEER database was explored to assess if the type of surgical approach is similar in black and white lung cancer patients METHODS: All cases of pathologically-proven lung cancers within the site recode ICD-O-3 C340-C349 (67,191 whites, 13,387 blacks), age < 64 years, diagnosed between 2007 and 2012 were identified...
August 17, 2016: Journal of Thoracic Oncology
Chun Chieh Lin, Katherine S Virgo, Anthony S Robbins, Ahmedin Jemal, Elizabeth M Ward
BACKGROUND: Physicians routinely factor comorbidities into diagnostic and treatment decisions. Analyses of treatment patterns and outcomes using the National Cancer Data Base (NCDB) usually adjust for comorbidities; however, the completeness of comorbidity ascertainment in the NCDB has never been assessed. We compared the prevalence of comorbidities captured in the NCDB and Surveillance, Epidemiology, and End Results (SEER)-Medicare among female breast, non-small-cell lung, and colorectal cancer patients aged ≥66...
December 2016: Annals of Surgical Oncology
Stephanie L Jarosek, Tetyana P Shippee, Beth A Virnig
OBJECTIVES: To use place-of-service (POS) codes in the Medicare hospice claims files to document where elderly hospice users with cancer die. DESIGN: Retrospective cohort study. SETTING: Surveillance, Epidemiology, and End Results (SEER) cancer registry areas. PARTICIPANTS: Elderly Medicare beneficiaries who died of lung, breast, colorectal, or pancreatic cancer in 2007 and 2008 (N = 46,037). MEASUREMENT: Use of hospice, place of service at death (home, nursing home, hospital, inpatient hospice, other), length of stay in hospice...
September 2016: Journal of the American Geriatrics Society
Jessica L Krok-Schoen, James L Fisher, Ryan D Baltic, Electra D Paskett
BACKGROUND: Increased life expectancy, growth of minority populations, and advances in cancer screening and treatment have resulted in an increasing number of older, racially diverse cancer survivors. Potential black/white disparities in cancer incidence, stage, and survival among the oldest old (≥85 years) were examined using data from the SEER Program of the National Cancer Institute. METHODS: Differences in cancer incidence and stage at diagnosis were examined for cases diagnosed within the most recent 5-year period, and changes in these differences over time were examined for white and black cases aged ≥85 years...
August 15, 2016: Cancer Epidemiology, Biomarkers & Prevention
Johnathan D Ebben, Ming You
Lung cancer is a clinically difficult disease with rising disease burden around the world. Unfortunately, most lung cancers present at a clinically advanced stage. Of these cancers, many also present with brain metastasis which complicates the clinical picture. This review summarizes current knowledge on the molecular basis of lung cancer brain metastases. We start from the clinical perspective, aiming to provide a clinical context for a significant problem that requires much deeper scientific investigation...
September 2016: International Journal of Biochemistry & Cell Biology
Yijiu Ren, Chenyang Dai, Hui Zheng, Fangyu Zhou, Yunlang She, Gening Jiang, Ke Fei, Ping Yang, Dong Xie, Chang Chen
Because the need of clinical prognostic evaluation by specific metastatic organ, we aim to analyze the prognostic factors in lung cancer patients with M1b disease with Surveillance Epidemiology and End-Results database (SEER). This retrospective study evaluated lung cancer patients of adenocarcinoma (AD), squamous cell carcinoma (SQCC), and small cell lung cancer (SCLC) selected from SEER. We provided the prognostic correlates of overall survival (OS) and lung cancer-specific survival (LCSS) in this population...
July 18, 2016: Oncotarget
Julia Mantey, Julie Ruterbusch, Rafael Meza, Kendra Schwartz
BACKGROUND: American Community Survey (ACS) estimates are said to be uncertain for small areas and small population groups. The Surveillance, Epidemiology and End Results (SEER) database uses a decennial census extrapolation methodology to yield population estimates used by cancer researchers across the country. We compared metropolitan Detroit cancer incidence estimates calculated using ACS data to those using SEER population estimates, which we considered to be the gold standard. METHODS: We generated age-adjusted cancer incidence rate estimates for 1-year, 3-year and 5-year time periods (2005-2010) using SEER and ACS population estimates for four racial/ethnic groups by sex and cancer type for residents in the tri-county Detroit area...
August 2016: Cancer Epidemiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"